Pulmonary Fibrosis News and Research RSS Feed - Pulmonary Fibrosis News and Research

DNA strands predict life expectancy

DNA strands predict life expectancy

BYU biologist Jonathan Alder has a startling secret he doesn't freely share: he knows when most of us are going to die. [More]
UM SOM launches ‘Program in Lung Healing’ to develop treatments for acute respiratory failure

UM SOM launches ‘Program in Lung Healing’ to develop treatments for acute respiratory failure

University of Maryland School of Medicine (UM SOM) Dean E. Albert Reece, MD, PhD, MBA, and Jeffrey A. Rivest, MS, President and Chief Executive Officer of University of Maryland Medical Center (UMMC), today announced the official launch of a new "Program in Lung Healing," that will further the School's position as a national leader in research, education and clinical innovation for acute ailments of the lung and respiratory system. [More]
TERT mutations may make smokers more susceptible to emphysema

TERT mutations may make smokers more susceptible to emphysema

Mutations in a gene that helps repair damaged chromosome ends may make smokers — especially female smokers — more susceptible to emphysema, according to results of a new study led by Johns Hopkins Kimmel Cancer Center researchers. [More]
Biogen Idec, Columbia University Medical Center form $30 million genomics research alliance

Biogen Idec, Columbia University Medical Center form $30 million genomics research alliance

Biogen Idec and Columbia University Medical Center have formed a $30 million strategic alliance to conduct genetics discovery research on the underlying causes of disease and to identify new treatment approaches. As part of this agreement, a sequencing and analysis facility and shared postdoctoral program will be established at Columbia to support collaborative genetics studies. [More]
2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet (pirfenidone)

2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet (pirfenidone)

This year's prestigious Canadian Prix Galien for Innovative Product Award has been presented to Esbriet (pirfenidone), a medicine used to treat idiopathic pulmonary fibrosis (IPF). It is the only medication approved in Canada with a specific IPF indication and is approved for mild to moderate IPF in adults. [More]
Excess fat in lungs may cause pulmonary fibrosis

Excess fat in lungs may cause pulmonary fibrosis

Pulmonary fibrosis has no cure. It's caused by scarring that seems to feed on itself, with the tougher, less elastic tissue replacing the ever moving and stretching lung, making it increasingly difficult for patients to breathe. [More]
Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF). [More]
Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim today announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States. [More]
Yale University researchers study potential new treatment to reverse effects of pulmonary fibrosis

Yale University researchers study potential new treatment to reverse effects of pulmonary fibrosis

Yale University researchers are studying a potential new treatment that reverses the effects of pulmonary fibrosis, a respiratory disease in which scars develop in the lungs and severely hamper breathing. [More]

Researchers suggest that proportion of IPF may be due to unknown exposure to asbestos

A proportion of idiopathic pulmonary fibrosis cases may be linked with asbestos exposure, according to the results of a new study. [More]
New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

Boehringer Ingelheim today presented new data from the company's Phase III trial program (UniTinA-asthma®) evaluating tiotropium in asthma, including the first study assessing the efficacy and safety of tiotropium in adolescent patients with symptomatic asthma. [More]
Viewpoints: Medicare no longer 'busting' the budget; a 'nightmare' trying to get coverage in D.C.

Viewpoints: Medicare no longer 'busting' the budget; a 'nightmare' trying to get coverage in D.C.

You're looking at the biggest story involving the federal budget and a crucial one for the future of the American economy. Every year for the last six years in a row, the Congressional Budget Office has reduced its estimate for how much the federal government will need to spend on Medicare in coming years. [More]
Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans. [More]
FDA grants orphan-drug designation to Genoa's pirfenidone for treatment of IPF disease

FDA grants orphan-drug designation to Genoa's pirfenidone for treatment of IPF disease

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, today announced the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to Genoa for the use of pirfenidone in their lead program - inhaled GP-101 for the treatment of IPF. [More]
Chronic obstructive pulmonary disease flare-ups: an interview with Dr. MeiLan Han, University of Michigan and Scott Cerreta, Director of Education, COPD Foundation

Chronic obstructive pulmonary disease flare-ups: an interview with Dr. MeiLan Han, University of Michigan and Scott Cerreta, Director of Education, COPD Foundation

During a flare-up, symptoms of a patient’s COPD worsen significantly, and breathing becomes more difficult. A persistent increase in shortness of breath, cough and sputum production are typical symptoms. [More]
Four major health institutions jointly receive $7 million for health data research network

Four major health institutions jointly receive $7 million for health data research network

Four major health institutions, including Penn State College of Medicine, have jointly received nearly $7 million to develop and expand a health data research network. [More]
Combined risk score enhances radiation pneumonitis prediction

Combined risk score enhances radiation pneumonitis prediction

Combining dose-volume histogram parameters with age and baseline pulmonary fibrosis score creates a novel predictive risk score that improves prediction of radiation pneumonitis in patients receiving concurrent chemoradiotherapy for non-small-cell lung cancer, research shows. [More]
FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation to nintedanib, an investigational therapy currently under FDA review for the treatment of people with idiopathic pulmonary fibrosis (IPF). [More]
Emphysema does not worsen lung cancer prognosis beyond pulmonary fibrosis

Emphysema does not worsen lung cancer prognosis beyond pulmonary fibrosis

Patients with combined pulmonary fibrosis and emphysema who are undergoing treatment for advanced lung cancer do not have a significantly worse prognosis than their counterparts with isolated idiopathic interstitial pneumonias, report Japanese researchers. [More]
Gene variants that lead to longer telomeres boost brain cancer risk

Gene variants that lead to longer telomeres boost brain cancer risk

New genomic research led by UC San Francisco scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas. [More]